Highlights of Ophthalmology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  52 (2024)
Volume  51 (2023)
Volume  50 (2022)
Volume  49 (2021)
Volume  48 (2020)
Volume  47 (2019)
Volume  46 (2018)
Volume  45 (2017)
Volume  44 (2016)
Volume  43 (2015)
Volume  42 (2014)
Volume  41 (2013)
Volume  40 (2012)
Volume  39 (2011)
Volume  38 (2009)
Related articles

VOLUME 43 , ISSUE 4ESP ( August, 2015 ) > List of Articles

REVIEW ARTICLE

Terapias Presentes y Futuras para tratar Degeneración Macular Relacionada con la Edad

Muhammad Khan, Ketan Agarwal, Mohamed Loutfi, Ahmed Kamal

Citation Information : Khan M, Agarwal K, Loutfi M, Kamal A. Terapias Presentes y Futuras para tratar Degeneración Macular Relacionada con la Edad. 2015; 43 (4ESP):13-17.

DOI: 10.5005/hos-10101-43404

Published Online: 27-09-2017

Copyright Statement:  Copyright © 2015; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract
PDF Share
  1. D. Pascolini and S. P. Mariotti, “Global estimates of visual impairment: 2010,” British Journal of Ophthalmology, vol. 96, no. 5, pp. 614-618, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Congdon, B. O'Colmain, C. C. Klaver, et al., “Causes and prevalence of visual impairment among adults in the United States,” Archives of Ophthalmology, vol. 122, no. 4, pp. 477-485, 2004. View at Google Scholar
  3. F. L. Ferris III, C. P. Wilkinson, A. Bird, et al., “Clinical classification of age-related macular degeneration,” Ophthalmology, vol. 120, no. 4, pp. 844-851, 2013. View at Google Scholar
  4. L. S. Lim, P. Mitchell, J. M. Seddon, F. G. Holz, and T. Y. Wong, “Age-related macular degeneration,” The Lancet, vol. 379, no. 9827, pp. 1728-1738, 2012. View at Google Scholar · View at Scopus
  5. U. Chakravarthy, J. Evans, and P. J. Rosenfeld, “Age related macular degeneration,” British Medical Journal, vol. 340, p. c981, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. C. G. Owen, Z. Jarrar, R. Wormald, D. G. Cook, A. E. Fletcher, and A. R. Rudnicka, “The estimated prevalence and incidence of late stage age related macular degeneration in the UK,” British Journal of Ophthalmology, vol. 96, no. 5, pp. 752-756, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. D. B. Rein, P. Zhang, K. E. Wirth et al., “The economic burden of major adult visual disorders in the United States,” Archives of Ophthalmology, vol. 124, no. 12, pp. 1754-1760, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. B. A. Syed, J. B. Evans, and L. Bielory, “Wet AMD market,” Nature Reviews Drug Discovery, vol. 11, no. 11, p. 827, 2012. View at Google Scholar
  9. S. L. Fine, J. W. Berger, M. G. Maguire, and A. C. Ho, “Age-related macular degeneration,” The New England Journal of Medicine, vol. 342, no. 7, pp. 483-492, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. H. R. Coleman, C. C. Chan, F. L. Ferris III, and E. Y. Chew, “Age-related macular degeneration,” The Lancet, vol. 372, no. 9652, pp. 1835-1845, 2008. View at Google Scholar11. T. H. Tezel, N. S. Bora, and H. J. Kaplan, “Pathogenesis of age-related macular
  11. 10, no. 9, pp. 417-420, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Z. Nowak, “Age-related macular degeneration (AMD): pathogenesis and therapy,” Pharmacological Reports, vol. 58, no. 3, pp. 353-363, 2006. View at Google Scholar · View at Scopus
  13. Ophthalmologists TRCo, “Statement from The Royal College of Ophthalmologists in response to the positive draft final guidance from NICE for Eylea,” http://www.rcophth.ac.uk/news.asp?itemid=1390&itemTitle=College+Statement+in+response+to+the+positive+draft+final+guidance+from+NICE+for+Eylea%AE+for+the+treatment+on+wAMD§ion=24§ionTitle=News2013.
  14. Ophthalmologists TRCo, “Bevacizumab. (Avastin). use. in. medical. ophthalmology,” http://www.rcophth.ac.uk/core/core_picker/download.asp?id=11812011.
  15. T. Moutray and U. Chakravarthy, “Age-related macular degeneration: current treatment and future options,” Therapeutic Advances in Chronic Disease, vol. 2, no. 5, pp. 325-331, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. D. M. Brown, P. K. Kaiser, M. Michels et al., “Ranibizumab versus verteporfin for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1432-1444, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1419-1431, 2006. View at Publisher · View at Google Scholar · View at Scopus 18. N. M. Bressler, D. S. Boyer, D. F. Williams, et al., “Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials,” Retina, vol. 32, no. 9, pp. 1821-1828, 2012. View at Google Scholar
  18. D. F. Martin, M. G. Maguire, S. L. Fine, et al., “Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results,” Ophthalmology, vol. 119, no. 7, pp. 1388-1398, 2012. View at Google Scholar
  19. U. Chakravarthy, S. P. Harding, C. A. Rogers, et al., “Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial,” The Lancet, vol. 382, no. 9900, pp. 1258-1267, 2013. View at Google Scholar
  20. J. S. Heier, D. Boyer, Q. D. Nguyen et al., “The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing,” Ophthalmology, vol. 118, no. 6, pp. 1098-1106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. J. S. Heier, D. M. Brown, V. Chong, et al., “Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration,” Ophthalmology, vol. 119, no. 12, pp. 2537-2548, 2012. View at Google Scholar
  22. Excellence NIfHaC, “Aflibercept solution for injection for treating wet age-related macular degeneration,” 2013.
  23. S. Schaal,. H. J. Kaplan,. and. T. H. Tezel, “Is. There. Tachyphylaxis. to. Intravitreal. Anti-Vascular. Endothelial. Growth. Factor Pharmacotherapy in Age-Related Macular Degeneration?” Ophthalmology, vol. 115, no. 12, pp. 2199-2205, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Barak, W. J. Heroman, and T. H. Tezel, “The past, present, and future of exudative age-related macular degeneration treatment,” Middle East African Journal of Ophthalmology, vol. 19, no. 1, pp. 43-51, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. A. J. Augustin, S. Puls, and I. Offermann, “Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone,” Retina, vol. 27, no. 2, pp. 133-140, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Zhang, L. Zhang, and R. N. Weinreb, “Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma,” Nature Reviews Drug Discovery, vol. 11, no. 7, pp. 541-559, 2012. View at Google Scholar
  27. K. Takahashi, Y. Saishin, Y. Saishin, A. G. King, R. Levin, and P. A. Campochiaro, “Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib,” Archives of Ophthalmology, vol. 127, no. 4, pp. 494-499, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. P. A. Campochiaro, “Gene transfer for neovascular age-related macular degeneration,” Human Gene Therapy, vol. 22, no. 5, pp. 523-529, 2011. View at Google Scholar
  29. R. Petrarca, P. U. Dugel, M. Bennett, et al., “Macular epiretinal brachytherapy in treated age-related macular degeneration (meritage): month 24 safety and efficacy results,” Retina, 2013. View at Publisher · View at Google Scholar
  30. P. U. Dugel, R. Petrarca, M. Bennett et al., “Macular epiretinal brachytherapy in treated age-related macular degeneration. MERITAGE study: twelve-month safety and efficacy results,” Ophthalmology, vol. 119, no. 7, pp. 1425-1431, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. P. U. Dugel, J. D. Bebchuk, J. Nau, et al., “Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET),” Ophthalmology, vol. 120, no. 2, pp. 317-327, 2013. View at Google Scholar
  32. T. L. Jackson, U. Chakravarthy, P. K. Kaiser, et al., “Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study,” Ophthalmology, vol. 120, no. 9, pp. 1893-1900, 2013. View at Google Scholar
  33. J. C. Lai, D. J. Lapolice, S. S. Stinnett et al., “Visual outcomes following macular translocation with 360° peripheral retinectomy,” Archives of Ophthalmology, vol. 120, no. 10, pp. 1317-1324, 2002. View at Google Scholar · View at Scopus
  34. C. I. Falkner-Radler, I. Krebs, C. Glittenberg et al., “Human retinal pigment epithelium (RPE) transplantation: outcome after autologous RPE-choroid sheet and RPE cell-suspension in a randomised clinical study,” British Journal of Ophthalmology, vol. 95, no. 3, pp. 370-375, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. T. H. Tezel and L. V. del Priore, “Repopulation of different layers of host human Bruch's membrane by retinal pigment epithelial cell grafts,” Investigative Ophthalmology and Visual Science, vol. 40, no. 3, pp. 767-774, 1999. View at Google Scholar · View at Scopus
  36. S. D. Schwartz, J.-P. Hubschman, G. Heilwell et al., “Embryonic stem cell trials for macular degeneration: a preliminary report,” The Lancet, vol. 379, no. 9817, pp. 713-720, 2012. View at Publisher View at Google Scholar · View at Scopus
  37. Z. Yehoshua, P. J. Rosenfeld, and T. A. Albini, “Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures,” Seminars in Ophthalmology, vol. 26, no. 3, pp. 167-180, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. S.-Y. Cohen, H. Bourgeois, C. Corbe et al., “Randomized clinical trial france DMLA2: effect of trimetazidine on exudative and lated macular degeneration,” Retina, vol. 32, no. 4, pp. 834-843, 2012. View at Publisher View at Googlew at Scopus.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.